MDACC Study No:2009-0239 ( NCT No: NCT00920140)
Title:An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib (GSK1120212) in Subjects with Relapsed or Refractory Leukemias
Principal Investigator:Gautam Borthakur
Treatment Agent:GSK1120212
Study Status:Terminated
Study Description:The goal of Phase 2 of this clinical research study is to learn if Trametinib
(GSK1120212) can help to control leukemia. The safety of this drug will also
be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:GSK1120212
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:GlaxoSmithKline
Return Visit:Every 4 weeks while on study.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults